
Hospira Reappoints chief scientific officer
pharmafile | May 15, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Hospira
Injectable drugs and infusion tech firm Hospira has announced that Sumant Ramachandra has been reappointed to his role as senior vice president and chief scientific officer.
He will resume responsibility for Hospira’s global R&D, regulatory and medical affairs organisation. Ramachandra returns to Hospira after a brief departure earlier this year and will serve as a member of the company’s senior leadership team, led by F. Michael Ball, Hospira’s chief executive.
“On behalf of our 16,000 employees, I’m thrilled to welcome Sumant back to the Hospira team,” said Ball. “Under Sumant’s leadership, Hospira has established one of the most robust biosimilars pipelines in the industry, expanded an already market-leading generic injectables portfolio and built a talented scientific, medical and regulatory organisation to execute our vision for future success.
“While we had interviewed an exceptional slate of candidates for this role, we determined that Sumant remained not only the best fit, but also would be best positioned to seamlessly advance our R&D priorities.”
Ramachandra added: “I’m energised by the opportunity to return to Hospira – to rejoin the talented employees and exciting future that drew me to the company nearly five years ago. My short time away has reignited my passion for the tremendous opportunities ahead.”
Related Content

Hospira in US-wide recall of product due to contamination
Hospira, a company owned by Pfizer, has been forced to recall a batch of injectable …
ICU Medical to acquire Pfizer’s global infusion therapy business in $1 billion deal
The $1 billion deal that will take place as ICU Medical Inc. take over Pfizer’s …

Pfizer may sell off Hospira unit for $2 billion
Pfizer is reportedly considering selling Hospira’s infusion pump business for around $2 billion, having acquired …






